|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9000 EUR | +1.01% |
|
-5.26% | -23.60% |
| 02/06 | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | CI |
| 01/06 | NFL Biosciences validates breakthrough in personalized medicine |  |
Company Valuation: NFL Biosciences
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 12.56 | 10.29 | 11.67 | 19.12 | 14.93 |
| Change | - | -18.12% | 13.49% | 63.78% | -21.92% |
| Enterprise Value (EV) 1 | 9.443 | 9.155 | 9.206 | 17.05 | 13.31 |
| Change | - | -3.05% | 0.56% | 85.17% | -21.93% |
| P/E Ratio | -12.8x | -4.21x | -3.14x | -9.56x | -4.62x |
| PBR | 3.82x | 12.2x | 33.6x | 19.8x | 48.8x |
| PEG | - | -0x | 1.88x | 0.2x | -0.2x |
| Capitalization / Revenue | 3,22,130x | 4,67,546x | 58.4x | 4,15,647x | 79,404x |
| EV / Revenue | 2,42,134x | 4,16,129x | 46x | 3,70,592x | 70,790x |
| EV / EBITDA | -11x | -3.02x | -2.21x | -6.26x | -3.51x |
| EV / EBIT | -10.5x | -2.97x | -2.18x | -6.11x | -3.44x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.1869 | -0.4668 | -0.459 | -0.206 | -0.255 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 0.000039 | 0.000022 | 0.2 | 0.000046 | 0.000188 |
| EBITDA 1 | -0.8584 | -3.031 | -4.174 | -2.723 | -3.786 |
| EBIT 1 | -0.9019 | -3.083 | -4.23 | -2.79 | -3.873 |
| Net income 1 | -0.9782 | -2.443 | -3.745 | -2.081 | -3.318 |
| Net Debt 1 | -3.12 | -1.131 | -2.467 | -2.073 | -1.619 |
| Reference price 2 | 2.4000 | 1.9650 | 1.4400 | 1.9700 | 1.1780 |
| Nbr of stocks (in thousands) | 5,235 | 5,235 | 8,107 | 9,705 | 12,672 |
| Announcement Date | 29/04/22 | 28/04/23 | 14/04/25 | 14/04/25 | 27/04/26 |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.32Cr | |
| 33.17x | 8.64x | 26.13x | 0.05% | 5.64TCr | |
| 16.69x | 5.03x | 10.91x | 1.8% | 4.45TCr | |
| -17.8x | 4.17x | -7.3x | -.--% | 2.29TCr | |
| -36.36x | 12.23x | -35.67x | -.--% | 2.12TCr | |
| 20.25x | 3.95x | 10.26x | -.--% | 1.64TCr | |
| 21.44x | 4.3x | 14.23x | -.--% | 1.54TCr | |
| 16.8x | 4.85x | 11.36x | -.--% | 1.34TCr | |
| -433.48x | 29.5x | -3289.39x | -.--% | 1.24TCr | |
| 36.9x | 14.16x | 41.61x | 0.18% | 1.12TCr | |
| Average | -38.04x | 9.65x | -357.54x | 0.23% | 2.14TCr | |
| Weighted average by Cap. | -12.27x | 8.35x | -180.62x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNFL Stock
- Valuation NFL Biosciences
Select your edition
All financial news and data tailored to specific country editions
